Application 219199
- Type
- ANDA
- Sponsor
- ALEMBIC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | DOXORUBICIN HYDROCHLORIDE | INJECTABLE, LIPOSOMAL;INJECTION | 20MG/10ML (2MG/ML) | No | No |
| 002 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | DOXORUBICIN HYDROCHLORIDE | INJECTABLE, LIPOSOMAL;INJECTION | 50MG/25ML (2MG/ML) | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A219199-001 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | |
| A219199-002 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A219199-001 | AB |
| A219199-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A219199-001 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A219199-002 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219199-001 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219199-002 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A219199-001 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A219199-002 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | 6a471c1ec25d… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219199-001 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219199-002 | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL / INJECTION | AB | 2025-06-27 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A219199-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A219199-002 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219199-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219199-002 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A219199-001 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A219199-002 | AB | 1 | 6a471c1ec25d… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219199-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219199-002 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | BluePoint Laboratories | 55889588-c5f1-d9bc-e063-6294a90a5791 | 2026-07-09 | Boxed warning, Warnings, Adverse reactions | 219199 ANDA219199 |
| doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | Dr. Reddy's Laboratories Inc. | 0885dddf-727e-4692-92dd-a26c69cc278d | 2025-11-29 | Boxed warning, Warnings, Adverse reactions | 219199 ANDA219199 |
| doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | Alembic Pharmaceuticals Inc. | c9cb8a8d-944f-4fe1-bfba-c55904a79fda | 2025-07-01 | Boxed warning, Warnings, Adverse reactions | 219199 ANDA219199 |
| doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | Alembic Pharmaceuticals Limited | f8e001f5-441c-47cd-86f6-5d5e3de16bc0 | 2025-07-01 | Boxed warning, Warnings, Adverse reactions | 219199 ANDA219199 |